Veloxis Pharmaceuticals, Inc.

Veloxis Pharmaceuticals, Inc. is a specialty pharmaceutical company that is dedicated to enhancing the lives of transplant patients. Operating as a subsidiary of Asahi Kasei, the company is headquartered in Cary, North Carolina, USA and focuses on the global development and commercialization of medications for transplant patients and those with related serious diseases. Founded in 2002, Veloxis Pharmaceuticals is deeply committed to innovating and addressing the challenges faced by transplant patients, aiming to improve their overall experience. The company's dedication to the transplant community is exemplified in its slogan, "Let's transform transplant medicine. Together," and its profound understanding of the significance of organ transplants in patients' lives. An important milestone in the company's growth trajectory was the $60.00M Post-IPO Debt investment on 14 February 2018, led by Athyrium Capital Management, which signified a critical point in its expansion and strategic development. As the company continues to make advancements in the Biotechnology, Health Care, and Pharmaceutical industries, it remains dedicated to its mission of improving the transplant journey for patients globally. Interested readers can access Veloxis Pharmaceuticals' Community Guidelines via this link: https://bit.ly/3FQr7Wg.